Patents Assigned to Institut National de la Sante et de la Recherche Medicale
  • Patent number: 11186634
    Abstract: The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: November 30, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse, Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse, Institut Claudius Regaud
    Inventors: Mary Poupot, Loïc Ysebaert, Marie Tosolini, Jean-Jacques Fournie, Pierre Brousset, Philippe Rochaix
  • Patent number: 11179449
    Abstract: The invention relates to combinations of peptides carrying T-cell epitopes of the antigen preprocalcitonin, presented by the MHC. These peptides can be used in anti-tumour immunotherapy.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: November 23, 2021
    Assignees: Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale, Université Paris-Saclay
    Inventors: Fathia Mami-Chouaib, Aurélie Durgeau
  • Patent number: 11180556
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: November 23, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 11179478
    Abstract: The present invention relates to the use of at least one tetra functional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: November 23, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventor: Bruno Pitard
  • Publication number: 20210353439
    Abstract: Methods and systems are provided for decoding movement intentions using functional ultrasound (fUS) imaging of the brain. In one example, decoding movement intentions include determining a memory phase of a cognitive state of the brain, the memory phase between a gaze fixation phase and movement execution phase, and determining one or more movement intentions including one or more of intended effector (e.g., hand, eye) and intended direction (e.g., right, left) according to a machine learning algorithm trained to classify one or more movement intentions simultaneously.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 18, 2021
    Applicants: California Institute of Technology, INSERM (Institut National de la Santé et de la Recherche Médicale), CNRS-CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Ecole Supérieure de Physique et de Chimie Industrielles de la Ville de Paris
    Inventors: Sumner L Norman, David Maresca, Vasileios Christopoulos, Mikhail Shapiro, Richard A. Andersen, Mickael Tanter, Charlie Demene
  • Patent number: 11176727
    Abstract: This method for acquiring a spatial map of auditory perception of a subject comprises a plurality of successive test sequences, each test sequence comprising steps of: a) calibration (1002) of the subject's position, by displaying instructions to the subject, using a head-mounted visual display system worn by the subject, in order to acquire a reference position of the subject, the subject's position being measured using a video motion capture system by measuring the spatial coordinates of a first optical marker worn by the subject, b) choosing (1004) spatial coordinates of a target location of a sound source, said target cation being located around the subject, c) emitting (1006) a predefined sound, using a sound source placed at said target location, d) in response to acquisition instructions generated by the subject using an acquisition interface, acquiring (1008) an estimated location of said sound source, by using the video motion capture system to measure the spatial coordinates of a second optical mark
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: November 16, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE JEAN MONNET SAINT ETIENNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Romeo Salemme, Alessandro Farne, Valérie Gaveau, Anaël Belle, Eric Koun, Francesco Pavani
  • Patent number: 11174322
    Abstract: The present invention relates to the treatment of HCMV relates diseases. The inventors conducted a study to find an essential domain of pUL56 for its interaction with pUL89 which is important in the effect of the CMV. Sequences alignments allowed them to predict one sequence in C-terminal of pUL56 potentially necessary for interaction with pUL89. BAC mutagenesis and AlphaLISA technologies using purified proteins allowed to validate that the short sequence 671WMVVKYMGFF680 (SEQ ID NO: 1) in C-terminal of pUL56 is involved in interaction with pUL89. Knowing this important information, antibodies directed against this sequence or peptides derived from this sequence could be useful to invalidate the interaction of pUL56 to pUL89 and thus to treat HCMV related diseases.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: November 16, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE HOSPITALIER Régional Universitaire de Limoges, Universitéde Limoges
    Inventors: Sophie Alain, Gaëtan Ligat, Sébastien Hantz, Anthony Couvreux
  • Publication number: 20210346238
    Abstract: The present teachings relate to a device and a method for treating a subject, wherein an actuator is configured for external mechanical contact with the subject, wherein a control unit is configured to control the actuator to provide at least one burst of a primary vibration, and wherein the primary vibration has one or several frequencies, or a frequency varying, within an operative frequency range contained in a range from 5 Hz to 1000 Hz, in order for the device to generate a shear wave which propagates inside the body of the subject. In addition, the present teachings relate to use of a device of the present teachings to treat a breathing-related sleep disorder, including snoring, OSA, UARS, or OHS.
    Type: Application
    Filed: October 3, 2018
    Publication date: November 11, 2021
    Applicants: BREAS MEDICAL AB, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Didier MENGUY, Jean-Yves CHAPELON, Stefan CATHELINE, Ali ZORGANI
  • Patent number: 11154625
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: October 26, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS 13
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans
  • Patent number: 11147868
    Abstract: The present invention generally relates to an immunogenic construct, useful for redirecting an EBV-existing immune response towards an undesired target cell and/or microorganism, to methods for preparing said conjugate, to a pharmaceutical applications comprising said conjugate, and to medical applications thereof.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: October 19, 2021
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Paris, Institut National Transfusion Sanguine
    Inventors: Arnaud Chene, Benoit Gamain, Stéphane Gangnard
  • Patent number: 11149314
    Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non invasive methods and kits for determining the quality of an embryo by determining the level of the cell free nucleic acids and/or determining the presence and/or expression level of at least one specific nucleic acid sequence in the nucleic acid extraction.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: October 19, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, Institut Régional du Cancer de Montpellier
    Inventors: Samir Hamamah, Safia El Messaoudi, Alain Thierry, Said Assou
  • Publication number: 20210308491
    Abstract: A therapy apparatus for treating tissue by the emission of focused ultrasound waves, including: a creation surface of a pressure field of focused ultrasound waves divided into at least N sectors having segments of asymmetrical concave curve (S1, S2, . . . ) with centres of curvature; centres of curvature (c1, c2, . . . ) asymmetrical to the extent where the centres of curvature are situated at different distances from the plane of symmetry (A1) or from the axis of symmetry (S) and/or at different depths taken according to the axis of symmetry; the individual axes (a1, a2, . . . ) intersecting between the focal zones (Zc1, Zc2, . . . ) and the creation surface (8) or beyond the focal zones such that the beams originating from the sectors intersect to create a focal coverage zone (Zr) which is off-axis relative to the plane of symmetry (A1) or to the axis of symmetry (S); the sectors of this creation surface (8) creating energy deposit zones with profiles corresponding to the focal coverage zones (Zr).
    Type: Application
    Filed: April 1, 2021
    Publication date: October 7, 2021
    Applicants: EDAP TMS FRANCE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE LEON BERARD
    Inventors: Marine SANCHEZ, David MELO DE LIMA, Jérémy VINCENOT
  • Publication number: 20210309718
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth regardation disorders, such as achondroplasia.
    Type: Application
    Filed: April 20, 2021
    Publication date: October 7, 2021
    Applicants: Pfizer Inc., INSERM (Institut National de la Santé et de la Recherche Médicale), Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • Patent number: 11135443
    Abstract: System (1) for treatment by photodynamic therapy comprising an illuminating member (6) which comprises: —a core (35) carrying a light emitting surface (37), and —a hollow sheath (10) adapted to receive the core (35) with the light emitting surface (37) arranged within a balloon (11), the balloon (11) comprising a wall (12) which has an inner surface delimiting an internal space, and an outer surface, the wall (12) being flexible, wherein the internal space of the balloon (11) has a variable capacity, the wall (12) of the balloon (11) being elastically extendible and the balloon (11) presenting a plurality of inflated states in each of which the internal space is filled with a volume of light diffusing solution, and wherein the system further comprises a support provided with a transfer function relating the volume of light diffusing solution of each inflated state with at least one of a corresponding distribution of light power at the outer surface of the wall (12) of the balloon (11) and a corresponding time
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: October 5, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Lille, Centre Hospitalier Regional et Universitaire de Lille (CHRU)
    Inventors: Maximilien Vermandel, Clement Dupont, Nicolas Reyns, Pascal Deleporte, Serge Mordon, Nacim Betrouni
  • Publication number: 20210301344
    Abstract: The present application describes and claims a novel method for identifying and stratifying the risk of developing a BK virus nephropathy (“Nx BK-v” below) in patients having undergone a kidney transplant. This method uses an index combining at least three bio-markers: i) the intensity of the anti-BK-v memory T lymphocyte response (memory T lymphocytes which are specific to v, hereinafter “LTm anti-BK-v”), ii) the number of occurrences of incompatibility in the HLA alleles of class I and class II between the donor and the recipient of the graft, taking into account iii) the viral charge of the BK-v virus in the whole blood of the patient. The present method allows a very precise evaluation of the risk of developing an Nx BK-v during the months following the test with the aim of optimising the immuno-suppressive treatment in order to better preserve the transplanted kidney.
    Type: Application
    Filed: June 18, 2019
    Publication date: September 30, 2021
    Applicants: UNIVERSITE PARIS-SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Yassine TAOUFIK, Antoine DURRBACH, Manon DEKEYSER
  • Patent number: 11130950
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cystic fibrosis. In particular, the present invention relates to a method of treating cystic fibrosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nucleic acid miR-9 inhibitor.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 28, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITÉ
    Inventors: Olivier Tabary, Florence Sonneville
  • Publication number: 20210282862
    Abstract: Systems, instruments, and methods are provided verifying that a robotic surgery is being performed in accordance with a surgical plan, wherein a surgical tool having a sensor outputs a data signal that enables the trajectory of the surgical tool to be displayed as an overlay on an image of an anatomical portion of a patient and a visual or audible signal that confirms the surgical tool is penetrating the anatomical portion in accordance with the surgical plan and/or that issues an alert indicating that the surgical tool is not being inserted into the anatomical portion according to the surgical plan.
    Type: Application
    Filed: May 28, 2021
    Publication date: September 16, 2021
    Applicants: SpineGuard, Sorbonne Universite, INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique - CNRS
    Inventors: Maurice BOURLION, Olivier FREZAL, Guillaume MOREL, Stephane BETTE, Thibault CHANDANSON, Florian RICHER, Valentin KERSPERN
  • Publication number: 20210278409
    Abstract: The present disclosure relates to methods for diagnosing hematological cancers. In particular, the present invention relates to a method for diagnosing a hematological cancer in a patient comprising i) detecting the presence of CD45RARO NK cells in a sample obtained from the patient and ii) and concluding that the patient suffers from a hematological cancer when the presence of CD45RARO NK cells is detected in the sample and the presence of at least one phenotypic marker indicates the nature of the haematological cancer.
    Type: Application
    Filed: March 4, 2021
    Publication date: September 9, 2021
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Martin Villalba Gonzalez, Ewelina Krzywinska
  • Patent number: 11104897
    Abstract: The present invention relates to compositions and methods for the treatment of nucleotide repeat expansion disorders such as myotonic dystrophy.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: August 31, 2021
    Assignees: GENETHON, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'EVRY VAL D'ESSONNE
    Inventors: Ana Maria Buj Bello, Mirella Lo Scrudato
  • Patent number: 11098124
    Abstract: Disclosed is CD31shed for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31shed ligand in different rat models of inflammation indeed showed that CD31shed is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31shed present on activated circulating cells and on other organs or cells not involved in inflammation was little. Also disclosed is a labeled CD31shed ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: August 24, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE PARIS, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Sylvie Bay, Antonino Nicoletti, Dominique Le Guludec, Jonathan Vigne, Giuseppina Caligiuri